Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaxis Ltd ( (AU:SNT) ) has provided an update.
Pharmaxis Ltd has released a statement regarding Syntara’s future financial position and product potential. The announcement highlights the uncertainties and risks involved in the development and commercialization of its product pipeline, emphasizing that actual outcomes may differ significantly from current expectations.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 11,836,801
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$43.95M
See more data about SNT stock on TipRanks’ Stock Analysis page.